

Received  
12-5-02

I hereby certify that this correspondence is being sent via Facsimile to  
Examiner Davis at 703-872-9307 On December 5, 2002

By: [Signature]Attorney Docket No.: 020093-000120US PATENT 160  
12-5-02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gerald P. Murphy et al.

Application No.: 09/016,737

Filed: January 30, 1998

For: ISOLATION AND/OR  
PRESERVATION OF DENDRITIC  
CELLS FOR PROSTATE CANCER  
IMMUNOTHERAPY

Examiner: Minh-Tam Davis

Art Unit: 1642

AMENDMENT REPLY/AFTER FINAL  
REJECTIONAssistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Final Rejection mailed July 5, 2002, please amend the  
above-identified application as follows:

IN THE CLAIMS:

Kindly replace claim 23 with the following substitute claim. An Appendix  
showing all changes to the claim is attached to this amendment as required by 37 C.F.R.  
§ 1.121(c).

23. (Five Times Amended) A composition comprising an isolated cell  
population exposed *in vitro* to a soluble prostate antigen, the cell population having an  
increased number of human dendritic cells competent and able to activate T cells specific  
to a prostate antigen as compared to an isolated cell population, comprising the same  
number of cells, that has not been exposed *in vitro* to the prostate antigen.

51  
On  
12/5/02